Icarus-breast01
WebbGustave Roussy 114, rue Édouard-Vaillant 94805 Villejuif Cedex - France Webb16 nov. 2024 · destiny-breast01研究是一项多中心、随机、开放ii期研究。 研究对象 ： 18岁及以上患者，明确的乳腺癌病理诊断，不可切除或转移性乳腺癌患者，her2阳性既往接受过t-dm1治疗，排除严重ild病史者，允许稳定的、经治的脑转移患者。 治疗分组 ：
Icarus-breast01
Did you know?
Webb28 okt. 2024 · DESTINY-Breast01：T-DXd治疗HER2+晚期乳腺癌的“开篇华章” DB-01研究是T-DXd在HER2+晚期乳腺癌领域初步探索的“开篇华章”。 这项国际多中心、开放标签、2期试验包括第一部分的PK、剂量探索阶段和第二部分的延续性阶段，入组患者是接受过T-DM1治疗的不可切除或转移性HER2+乳腺癌。 Webb1 juni 2024 · DESTINY-Breast01試験は、トラスツズマブ エムタンシン（T-DM1）治療を受けたHER2陽性の再発・転移を有する乳がん患者を対象としたグローバル第II相試験。 独立中央判定委員会による奏効率は60.9％、PFS中央値は16.4ヵ月であり、持続的な腫瘍縮小効果が示されている。 この結果に基づき、本邦では2024年3月に「化学療法歴の …
WebbThe name Icarus means 'he follows'. Variations of Icarus include Icaros, Ickaros, Ickarus, Ikaros, and Ikarus. See also the related categories, english and greek. Icarus is not … WebbTROPION-Breast01 (NCT05104866) is an ongoing, global, phase III, open-label, randomized trial evaluating efficacy and safety of Dato-DXd vs ICC in pts with inoperable or metastatic HR+/HER2– BC. Pts (n≈700) are randomized 1:1 to Dato-DXd 6 mg/kg IV Q3W or ICC (eribulin, capecitabine, vinorelbine, or gemcitabine) until progression.
Webb8 maj 2024 · Lead author Charles A. Powell of the Pulmonary Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, USA said that the phase II DESTINY-Breast01 study demonstrated strong efficacy of T-DXd in patients with pre-treated HER2-positive metastatic breast cancer. Webb19 sep. 2024 · 这是靶向人表皮生长因子受体2（HER2）的新一代抗体药物偶联物（ADC）药物 trastuzumab deruxtecan（T-DXd，又称DS-8201）头对头比较恩美曲妥珠单抗（T-DM1）用于HER2阳性晚期乳腺癌二线治疗的Ⅲ期随机对照试验，结果显示，DS-8201二线治疗较 T-DM1大幅降低肿瘤复发或死亡风险和延长无疾病进展生存 …
Webb15 aug. 2024 · The trial evaluated a similar later-line patient population as the single-arm DESTINY-Breast01 Phase II trial, which was the basis for initial approvals in advanced HER2-positive metastatic breast cancer. The safety profile of Enhertu in DESTINY-Breast02 was consistent with previous Phase III clinical trials with no new safety …
WebbUpdated safety analysis from DESTINY-Breast03 further confirmed the benefit-risk profile of ENHERTU for HER2+ mBC (5.4 mg/kg) demonstrated in prior studies1-4. Initial analysis (May 2024 data cutoff): Median duration of treatment was 14 months (range: 0.7 to 30) with ENHERTU and 7 months (range: 0.7 to 25) with T-DM1. ENHERTU 5.4 mg/kg. mcadams and morford drugstoreWebb1 sep. 2024 · The DESTINY-Breast01 study is a clinical study in participants with a type of breast cancer called HER2-positive breast cancer. The participants in the study received a treatment called trastuzumab deruxtecan, also known as T-DXd. The purpose of this summary is to help you understand the results of the DESTINY-Breast01 study. mcadam and turnbull toowoombaWebb19 jan. 2024 · Evaluation of Innovative Therapeutic Approaches of Vaginal and Sexual Dysfunction After Breast Cancer Treatment (EPIONE-01) The safety and scientific … mcadams and morford logoWebb30 dec. 2024 · In an updated analysis of the phase 2 DESTINY-Breast01 study, women with HER2-positive metastatic breast cancer taking antibody-drug conjugate trastuzumab deruxtecan continued to demonstrate favorable efficacy data, durable responses, overall survival rates, and a tolerable safety profile. Physician’s Weekly interviews lead study … mcadams 3 levels of personalityWebb8 maj 2024 · DESTINY-Breast01 is a pivotal Phase II, open-label, global, multicentre, two-part trial evaluating the safety and efficacy of trastuzumab deruxtecan in patients with … mcadams architectsWebb18 nov. 2024 · TROPION-Breast01 is a global, randomized, open-label, phase 3 trial evaluating the efficacy and safety of datopotamab deruxtecan (6 mg/kg) compared with … mcadams apartments houstonWebb18 nov. 2024 · About TROPION-Breast01 TROPION-Breast01 is a global, randomized, open-label, phase 3 trial evaluating the efficacy and safety of datopotamab deruxtecan (6 mg/kg) compared with investigator’s choice of chemotherapy (eribulin, capecitabine, vinorelbine or gemcitabine) in patients with inoperable or metastatic HR positive, HER2 … mcadams attendance center ms